ReviewFrontiers in pediatrics2026
Next-generation sequencing in the etiological diagnosis of severe childhood pneumonia.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pneumonia is the leading cause of death for children, particularly those aged 3-5 years old. The majority of the 740,000 annual global deaths of children under five years old occurred in developing countries in 2019. Severe childhood pneumonia (SCAP) causes death and disability in children, as it may trigger pleural effusion, respiratory failure, bacteremia and multiple organ failure. Traditional pathogen detection techniques including microscopy, culture and polymerase chain reaction (PCR) feature narrow detection coverage, lengthy detection cycles and low sensitivity. These defects frequently lead to undetermined infectious etiology, forcing clinicians to administer empirical broad-spectrum antibiotics. Metagenomic next-generation sequencing (mNGS) has emerged as an innovative, high-throughput, untargeted detection technology in recent years, which greatly promotes the etiological diagnosis of infectious diseases. Published meta-analyses show that the pathogen detection rate of mNGS using bronchoalveolar lavage fluid (BALF) samples collected from children can reach 85.83%, which is markedly higher than the 49.97% detection rate of conventional testing approaches. This review systematically elaborates how mNGS reconstructs the cognition of pathogen spectrum in children with severe pneumonia: this technology accurately identifies complex mixed infection patterns, detects pathogens that cannot be captured by traditional testing, and redefines the clinical boundary between microbial colonization and invasive infection. Combined with latest clinical research data, this paper analyzes the core value of mNGS in optimizing treatment schemes, reducing irrational antibiotic use and realizing precision therapy for severe pneumonia in children. Meanwhile, the current limitations and future development directions of this technology are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.